Abstracts tagged "patient-reported outcome measures and rheumatoid arthritis (RA)"

Abstract Number: 2547 • 2018 ACR/ARHP Annual Meeting
Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Vibeke Strand¹, Maya Buch², Namita Tundia³, Heidi S. Camp³, Jessica Suboticki³, Debbie Goldschmidt⁴ and Alvin F. Wells⁵, ¹Stanford University, Palo Alto, CA, ²NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group Inc., New York, NY, ⁵Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: Upadacitinib (UPA) is a selective JAK-1 inhibitor with demonstrated patient-reported benefits in the treatment of active rheumatoid arthritis (RA).1,2 The objective of this analysis…
Abstract Number: 2869 • 2018 ACR/ARHP Annual Meeting
Incorporation of Patient Reported Outcomes Data in the Care of US Veterans with Rheumatoid Arthritis: A Randomized, Controlled Trial
Michael R Bubb¹, Reuben Judd¹ and Ann D Chauffe², ¹Medicine, Malcom Randall VAMC, Gainesville, FL, ²Rheumatology Clinic of Opelousas, Opelousas, LA
Background/Purpose: Quantitative disease activity measures are required to implement a treat-to-target algorithm for the treatment of rheumatoid arthritis (RA). Available measures based on patient-derived data…
Abstract Number: 2358 • 2018 ACR/ARHP Annual Meeting
Risk Factors for Persistent Discordance in Global Assessment of Rheumatoid Arthritis (RA) Disease Activity between RA Patients and Their Physicians: Analysis Based on a Nationwide RA Database (2011 to 2016)
Tetsuji Sawada¹, Susumu Nishiyama², Mayu Tago³, Koichiro Tahara³, Eri Kato¹, Hiroaki Mori³, Haeru Hayashi³, Toshihiro Matsui⁴, Jinju Nishino⁵ and Shigeto Tohma⁶, ¹Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ²Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan, ³Rheumatology, Tokyo Medical University, Tokyo, Japan, ⁴National Hospital Organization Sagamihara l Hospital, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan, ⁵Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ⁶National Hospital Organization Tokyo National Hospital, Kiyose, Japan
Background/Purpose: Discordance between patient global assessment (PGA) and physician global assessment (PhGA) of RA disease activity may be problematic in clinical practice. Previous studies, including…
Abstract Number: 2524 • 2018 ACR/ARHP Annual Meeting
Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs
Alvin F. Wells¹, Yvonne C. Lee², Namita Tundia³, Jessica Suboticki³, Kun Chen³, Alan Friedman³ and Vibeke Strand⁴, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³AbbVie Inc., North Chicago, IL, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Although treatment with csDMARDs and bDMARDs can lead to remission in patients with RA, many patients still experience pain and morning (AM) stiffness, which…
Abstract Number: 2531 • 2018 ACR/ARHP Annual Meeting
Assessment of Pain Relief with Baricitinib By Treatment History in Patients with Refractory Rheumatoid Arthritis
Janet E. Pope¹, Amanda Quebe², Baojin Zhu², Luna Sun², Carol L. Gaich², Francesco de Leonardis², Anabela Cardoso² and Mark C. Genovese³, ¹St. Joseph's Health Care, Divsion of Rheumatology, London, ON, Canada, ²Eli Lilly and Company, Indianapolis, IN, ³Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Baricitinib (BARI) 2 mg and 4 mg once daily demonstrated significant clinical improvements compared to placebo in the phase 3 study of RA patients…
Abstract Number: 133 • 2017 ACR/ARHP Annual Meeting
Impact of the Five Components of the Euroqol 5-Dimensions Instrument on Healthcare and Work-Loss Costs in Rheumatoid Arthritis: Observational Data from Southern Sweden
Anders Gülfe¹, Tor Olofsson¹, Jonas K Söderling², Martin Neovius² and Johan K Wallman¹, ¹Department of Clinical Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ²Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Healthcare and work-loss costs are markedly higher in RA patients than in the general population. The EuroQol 5-Dimensions (EQ-5D) instrument, commonly applied to measure…
Abstract Number: 352 • 2017 ACR/ARHP Annual Meeting
Psychometric Features of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients with Rheumatoid Arthritis (RA): Preliminary Results from an Online Patient Community
Elodie de Bock¹, Corrado Bernasconi², Tan P. Pham¹, Ana Maria Rodriguez³, Khaled Sarsour⁴, J. Michael Nebesky² and Christine de la Loge¹, ¹Mapi, Lyon, France, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Patients Like Me (PLM), Cambridge, MA, ⁴Genentech, South San Francisco, CA
Background/Purpose: F. Hoffmann-La Roche Ltd. and Mapi collaborated to develop a medication adherence measure among RA patients taking MTX—the Methotrexate Experience Questionnaire (MEQ). The MEQ…
Abstract Number: 501 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study
Vibeke Strand¹, Namita Tundia² and Alan Friedman², ¹Stanford University, Palo Alto, CA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Janus kinase (JAK) inhibitors are being evaluated for treatment of active rheumatoid arthritis (RA). The efficacy of upadacitinib (UPA), a selective JAK inhibitor, in…
Abstract Number: 510 • 2017 ACR/ARHP Annual Meeting
Association between Clinical Response and Normalization of Patient-Reported Outcome Measures in Rheumatoid Arthritis: Post-Hoc Analysis from Two Phase 2b Filgotinib Studies
Mark C. Genovese¹, Annegret Van der Aa², Corinne Jamoul², Chantal Tasset², Pille Harrison², René Westhovens³ and Arthur Kavanaugh⁴, ¹Stanford University Medical Center, Palo Alto, CA, ²Galapagos NV, Mechelen, Belgium, ³University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ⁴Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as…
Abstract Number: 2249 • 2017 ACR/ARHP Annual Meeting
Influence of Large-Joint Involvement on Patient-Physician Discordance in Global Assessment of Rheumatoid Arthritis Disease Activity Analyzed By Novel Joint Index
Tetsuji Sawada¹, Mayu Tago¹, Susumu Nishiyama², Koichiro Tahara¹, Eri Kato³, Hiroaki Mori¹, Haeru Hayashi¹, Jinju Nishino⁴, Toshihiro Matsui⁵ and Shigeto Tohma⁶, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Rheumatic Disease Center, Kurashiki Medical Center, Okayama, Japan, ³Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ⁴Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ⁵Department of Lifetime Clinical Immunology Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: The discordance between patient global assessment (PGA) and physician global assessment (PhGA) of rheumatoid arthritis (RA) disease activity may be problematic in clinical practice.…
Abstract Number: 455 • 2016 ACR/ARHP Annual Meeting
Validity, Reliability and Sensitivity to Change of Four Different Patient-Reported Outcomes (PROs) to Measure the Domains Pain, Fatigue, Experienced Disease Activity and General Well-Being in Patients with Rheumatoid Arthritis
Lisanne Renskers¹, Piet L.C.M. van Riel^2,3 and Ron J.J.C. van Uden¹, ¹IQ healthcare, Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, ²Radboud university medical center, Radboud Institute for Health Sciences, IQ healthcare, Nijmegen, Netherlands, ³Bernhoven, Department of Rheumatology, Uden, Netherlands
Background/Purpose: With Patient-Reported Outcomes (PROs), the patient's perspective can be assessed. Several forms can be used; Verbal Rating Scale (VRS), Numerical Rating Scale (NRS), Visual…
Abstract Number: 611 • 2016 ACR/ARHP Annual Meeting
Analysis of a German Subpopulation with Active Rheumatoid Arthritis Treated with Golimumab As Add-on Therapy to Disease-Modifying Antirheumatic Drugs
Hendrik Schulze-Koops¹, Jürgen Wollenhaupt², Marita Winnemöller³, Ines Klaudius³ and Helena Löffler³, ¹Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Schön Klinik Hamburg-Eilbek, Hamburg, Germany, ³Medical Affairs, MSD Sharp & Dohme GmbH, Haar, Germany
Background/Purpose: In previous clinical studies the human monoclonal TNFα-antibody golimumab (GLM) showed a good clinical response and a favorable benefit:risk profile in the treatment of…
Abstract Number: 148 • 2015 ACR/ARHP Annual Meeting
An Evaluation of the Virtual Monitoring Clinic, a Novel Nurse-Led Telemonitoring Service for Monitoring Patients with Stable Rheumatoid Arthritis
Li-Ching Chew¹, Julian Thumboo¹, Hui Yang² and Xiaohui Xin³, ¹Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²Division of Medicine, Singapore General Hospital, Singapore, Singapore, ³Academic Clinical Programme, Division of Medicine, Singapore General Hospital, Singapore, Singapore
Background/Purpose: To study the clinical and patient reported outcomes of the Virtual Monitoring Clinic (VMC), which is novel nurse-led telemonitoring cum pharmacy medication home delivery…
Abstract Number: 2321 • 2015 ACR/ARHP Annual Meeting
Performance of Patient Reported Outcomes in the Assessment of Rheumatoid Arthritis Disease Activity: The Experience of the Espoir Cohort
Hélène Che¹, Bernard Combe², Jacques Morel³, Alain G. Cantagrel⁴, Laure Gossec⁵ and Cédric Lukas⁶, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²Rheumatology, Hopital Lapeyronie, Montpellier, France, ³Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁴Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁵Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁶Hopital Lapeyronie, Montpellier, France
Background/Purpose: Activity of rheumatoid arthritis (RA) can be assessed by several outcome measures : joint counts, inflammatory syndrom but also auto-questionnaires such as global patient…
Abstract Number: 2624 • 2015 ACR/ARHP Annual Meeting
Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis
Anna Kristina Gutierrez¹, Michelle Jones², Susan J. Bartlett^1,3,4 and Clifton O. Bingham III², ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁴Medicine , Divisions of Clinical Epidemiology, Rheumatology, Respirology, McGill University, Montreal, QC, Canada
Background/Purpose: The process of patient reported outcome (PRO) validation requires demonstration that the concept being measured and the patient experience of the corresponding symptom or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].